Abstract
Ligand-independent and/or proNGF-induced p75NTR signaling has emerged as a potential major contributor to a number of pathological states, including axotomy-induced death, motor neuron degeneration, neuronal degeneration in Alzheimers disease and oligodendrocyte death following spinal cord injury. A long standing goal in the neurotrophin field has been the development of non-peptide, small molecules capable of functioning as specific ligands at neurotrophin receptors such as p75NTR to promote desired biological outcomes. Synthetic peptides modeled on neurotrophin protein domains have been found to bind to and activate various neurotrophin receptors, raising the possibility that active, nonpeptide, small molecule ligands might also be identified; however, traditional high-throughput screening approaches have been largely ineffective in identifying such compounds. Using pharmacophores derived from the structure of loop 1 of nerve growth factor, non-peptide, small molecules that function as p75NTR ligands to promote survival and block proNGFinduced death have recently been identified. Small molecule p75NTR ligands, with high potency and specificity, may provide novel therapeutic approaches for neurodegenerative diseases, neurotrauma and other pathologic states.
CNS & Neurological Disorders - Drug Targets
Title: Small Molecule Modulation of p75 Neurotrophin Receptor Functions
Volume: 7 Issue: 1
Author(s): Frank M. Longo, Frank M. Longo, Stephen M. Massa and Stephen M. Massa
Affiliation:
Abstract: Ligand-independent and/or proNGF-induced p75NTR signaling has emerged as a potential major contributor to a number of pathological states, including axotomy-induced death, motor neuron degeneration, neuronal degeneration in Alzheimers disease and oligodendrocyte death following spinal cord injury. A long standing goal in the neurotrophin field has been the development of non-peptide, small molecules capable of functioning as specific ligands at neurotrophin receptors such as p75NTR to promote desired biological outcomes. Synthetic peptides modeled on neurotrophin protein domains have been found to bind to and activate various neurotrophin receptors, raising the possibility that active, nonpeptide, small molecule ligands might also be identified; however, traditional high-throughput screening approaches have been largely ineffective in identifying such compounds. Using pharmacophores derived from the structure of loop 1 of nerve growth factor, non-peptide, small molecules that function as p75NTR ligands to promote survival and block proNGFinduced death have recently been identified. Small molecule p75NTR ligands, with high potency and specificity, may provide novel therapeutic approaches for neurodegenerative diseases, neurotrauma and other pathologic states.
Export Options
About this article
Cite this article as:
Longo M. Frank, Longo M. Frank, Massa M. Stephen and Massa M. Stephen, Small Molecule Modulation of p75 Neurotrophin Receptor Functions, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885093
DOI https://dx.doi.org/10.2174/187152708783885093 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Review of Polyhydroxyalkanoates Materials and other Biopolymers for Medical Applications
Mini-Reviews in Organic Chemistry Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design The Molecular Basis of Memantine Action in Alzheimers Disease and Other Neurologic Disorders: Low-affinity, Uncompetitive Antagonism
Current Alzheimer Research Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Painful Peripheral Neuropathies
Current Neuropharmacology New Perspectives on Acetaminophen
Current Cardiology Reviews Systemic Oxidative Stress in Older Patients with Mild Cognitive Impairment or Late Onset Alzheimer's Disease
Current Alzheimer Research Adult Stem Cell Application in Spinal Cord Injury
Current Drug Targets L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Heat Shock Proteins and Proteasome Function in Neurodegeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Discovery of Nesfatin-1 and Overview of Biological Actions and New Developments
Current Pharmaceutical Design Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents